demonstrated that a 3-day administration of ABR-238901 in an experimental mouse model of myocardial infarction conferred cardioprotective effects, primarily through the inhibition of S100A8/A9-induced upregulation of NADPH oxidase expression and activation of the NLRP3 inflammasome (106). Here, S100A8 is linked to myocardial infarction.